Evidence map›Paper›PMID 25461957›Full record

ArticlePloS one2014

Prosaposin overexpression following kainic acid-induced neurotoxicity.

Hiroaki Nabeka, Keigo Uematsu, Hiroko Takechi, Tetsuya Shimokawa, Kimiko Yamamiya, Cheng Li, Takuya Doihara, Shouichiro Saito, Naoto Kobayashi, Seiji Matsuda

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Tracking of Prosaposin, a Saposin Precursor, in Rat Testis.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Neuroproteomics in Epilepsy: What Do We Know so Far?Frontiers in molecular neuroscience · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hiroaki NabekaDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Keigo UematsuDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Hiroko TakechiDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Tetsuya ShimokawaDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Kimiko YamamiyaDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Cheng LiDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Takuya DoiharaDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Shouichiro SaitoLaboratory of Veterinary Anatomy, Faculty of Applied Biological Sciences, Gifu University, Yanagido, Gifu, Japan.
Naoto KobayashiMedical Education Center, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Seiji MatsudaDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Ehime University · JPGifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because excessive glutamate release is believed to play a pivotal role in numerous neuropathological disorders, such as ischemia or seizure, we aimed to investigate whether intrinsic prosaposin (PS), a neuroprotective factor when supplied exogenously in vivo or in vitro, is up-regulated after the excitotoxicity induced by kainic acid (KA), a glutamate analog. In the present study, PS immunoreactivity and its mRNA expression in the hippocampal and cortical neurons showed significant increases on day 3 after KA injection, and high PS levels were maintained even after 3 weeks. The increase in PS, but not saposins, detected by immunoblot analysis suggests that the increase in PS-like immunoreactivity after KA injection was not due to an increase in saposins as lysosomal enzymes after neuronal damage, but rather to an increase in PS as a neurotrophic factor to improve neuronal survival. Furthermore, several neurons with slender nuclei inside/outside of the pyramidal layer showed more intense PS mRNA expression than other pyramidal neurons. Based on the results from double immunostaining using anti-PS and anti-GABA antibodies, these neurons were shown to be GABAergic interneurons in the extra- and intra-pyramidal layers. In the cerebral cortex, several large neurons in the V layer showed very intense PS mRNA expression 3 days after KA injection. The choroid plexus showed intense PS mRNA expression even in the normal rat, and the intensity increased significantly after KA injection. The present study indicates that inhibitory interneurons as well as stimulated hippocampal pyramidal and cortical neurons synthesize PS for neuronal survival, and the choroid plexus is highly activated to synthesize PS, which may prevent neurons from excitotoxic neuronal damage. To the best of our knowledge, this is the first study that demonstrates axonal transport and increased production of neurotrophic factor PS after KA injection.

Indexed as

Gene Expression RegulationAnimalsCerebral CortexChoroid PlexusGABAergic Neuronsgamma-Aminobutyric AcidHippocampusIn Situ HybridizationInterneuronsKainic AcidLysosomesMaleMicroscopy, FluorescenceNerve DegenerationNeuronsNeurotoxicity Syndromesgamma-Aminobutyric AcidKainic AcidPSAP protein, humanSaposins

Identifiers

PMID25461957
PMCPMC4251898
OpenAlexW2065981469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.